Compare EOG Resources Inc (EOG) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EOG Resources Inc vs GSK plc — how do they compare? EOG Resources Inc trades at $148.6 (market cap $77.90B), while GSK plc trades at $46.62 (market cap $91.88B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold EOG Resources Inc for 59 Days and GSK plc for 93 Days on average.
| EOG | GSK | |
|---|---|---|
Market Cap | $77.90B | $91.88B |
Volume | 2,930,386 | 7,730,529 |
Sector | Energy | Health |
52-Week High | $153.74 | $61.18 |
52-Week Low | $101.78 | $43.24 |
Typical Hold Time | 59 Days | 93 Days |
Enterprise Value | $81.24B | $111.88B |
Dividend Yield | 2.75% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EOG Resources trades at $149.40, up 3.6% today, with a bullish technical outlook and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $5.07 exceeding expectations. Valuation ratios appear attractive, including a P/E of 11.56 and EV/EBITDA of 5.84. Recent news highlights robust operational execution and disciplined capital allocation, with the company announcing a CFO transition and scheduling its Q3 2026 earnings call for November 6.
The outlook for EOG remains positive, supported by strong profitability metrics, a solid balance sheet, and a unanimous analyst buy/hold consensus with no sell ratings. Key opportunities include projected revenue growth to $26.6B in 2026 and a 5% oil volume growth target. Risks involve exposure to volatile oil prices, as seen in recent price retreats impacting energy stocks, and potential execution challenges amid macroeconomic uncertainty. The stock offers value with a consensus price target of $164.77, implying ~10% upside.
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EOG Resources Inc
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
